Syncona Ltd - Company Profile
Powered by 
All the data and insights you need on Syncona Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Syncona Ltd Strategy Report
- Understand Syncona Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Syncona Ltd (Syncona) is a closed-ended investment company. Its services include founding, building, and funding companies. The company makes investments in life sciences companies including gene therapy, cell therapy, biologics, and small molecule fields. Syncona’s portfolio companies include Freeline Therapeutics, SwanBio Therapeutics, Neogene Therapeutics, Autolus, Quell Therapeutics, Anveon, Achilles Therapeutics, Clade Therapeutics, Purespring Therapeutics, OMass Therapeutics, and Resolution Therapeutics. The company also provides Syncona Platform which helps to transform scientific research into companies. It serves healthcare, biotechnology, pharmaceutical, life sciences, and other sectors. The company operates in the UK, the US and Switzerland. Syncona is headquartered in Saint Peter Port, Guernsey, the UK.
Headquarters
United Kingdom
Address
Arnold House, St Julian's Avenue, Saint Peter Port, Guernsey, GY13RD
Website
www.synconaltd.com
Industry
Financial Services
Ticker Symbol & Exchange
SYNC (LON)
EPS
XYZ
Net Income (2023)
XYZ
-733.8%
(2023 vs 2022)
Market Cap*
$1.0B
Net Profit Margin (2022)
XYZ
-30.1%
(2023 vs 2022)
* As of and is in US$
Products and Services
| Services |
|---|
| Service: |
| Investments in Life Sciences Companies |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company entered into an agreement to acquire Freeline Therapeutics Holdings plc. |
| 2023 | Contracts/Agreements | In June, Quell Therapeutics and AstraZeneca entered into an agreement to develop, manufacture and commercialise autologous, engineered Treg cell therapies for two autoimmune disease indications. |
| 2023 | Corporate Changes/Expansions | In June, the company launched Beacon Therapeutics Holdings Limited, an ophthalmic gene therapy company. |
Competitor Comparison
| Key Parameters | Syncona Ltd | Abingworth LLP | Advent Life Sciences LLP | Arix Bioscience Plc |
|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | Saint Peter Port | London | London | London |
| State/Province | Guernsey | England | England | England |
| No. of Employees | - | - | - | 7 |
| Entity Type | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Melanie Gee | Chairman | Executive Board | - | - |
| Markus John | Head - Research and Development; Chief Medical Officer | Senior Management | 2021 | - |
| Edward Hodgkin | Senior Partner-Syncona Investment Management Limited | Senior Management | - | - |
| Nikki Padden | Director - Finance | Senior Management | - | - |
| Martin Murphy | Chief Executive Officer - Syncona Investment Management Limited | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward